{
    "nct_id": "NCT06628310",
    "official_title": "A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)",
    "inclusion_criteria": "* Have inoperable, advanced or metastatic histologically- or cytologically confirmed gastric, gastroesophageal junction, or esophageal adenocarcinoma.\n* Have measurable disease determined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n* Human epidermal growth factor receptor 2 (HER2) negative disease, defined as immunohistochemistry (IHC) (0, or 1+) or fluorescence in situ hybridization (FISH) negative.\n* Known programmed death ligand 1 (PD-L1) status at screening, or availability of tumor tissue for local or central PD-L1 testing prior to enrollment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have prior systemic therapy in the locally advanced, unresectable, or metastatic setting.\n* History of clinically significant, intercurrent lung-specific illnesses including, but not limited to those listed in the protocol.",
    "miscellaneous_criteria": ""
}